These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. An update on the management of urinary tract infections in the era of antimicrobial resistance. Bader MS; Loeb M; Brooks AA Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137 [TBL] [Abstract][Full Text] [Related]
5. "Double carbapenem" and oral fosfomycin for the treatment of complicated urinary tract infections caused by bla Rosa R; Rudin SD; Rojas LJ; Hujer AM; Perez-Cardona A; Perez F; Bonomo RA; Martinez O; Abbo LM; Camargo JF Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29064133 [TBL] [Abstract][Full Text] [Related]
6. Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options. Origüen J; Fernández-Ruiz M; López-Medrano F; Ruiz-Merlo T; González E; Morales JM; Fiorante S; San-Juan R; Villa J; Orellana MÁ; Andrés A; Aguado JM Transpl Infect Dis; 2016 Aug; 18(4):575-84. PubMed ID: 27373698 [TBL] [Abstract][Full Text] [Related]
7. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Keating GM Drugs; 2013 Nov; 73(17):1951-66. PubMed ID: 24202878 [TBL] [Abstract][Full Text] [Related]
8. Retrospective evaluation of intravenous fosfomycin in multi-drug resistant infections at a tertiary care hospital in Lebanon. Ballouz T; Zeenny RM; Haddad N; Rizk N; Kanj SS J Infect Dev Ctries; 2021 Sep; 15(9):1308-1313. PubMed ID: 34669601 [TBL] [Abstract][Full Text] [Related]
9. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Bader MS; Loeb M; Leto D; Brooks AA Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743 [TBL] [Abstract][Full Text] [Related]
10. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Neuner EA; Sekeres J; Hall GS; van Duin D Antimicrob Agents Chemother; 2012 Nov; 56(11):5744-8. PubMed ID: 22926565 [TBL] [Abstract][Full Text] [Related]
11. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections. Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673 [TBL] [Abstract][Full Text] [Related]
12. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Falagas ME; Giannopoulou KP; Kokolakis GN; Rafailidis PI Clin Infect Dis; 2008 Apr; 46(7):1069-77. PubMed ID: 18444827 [TBL] [Abstract][Full Text] [Related]
13. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Patel SS; Balfour JA; Bryson HM Drugs; 1997 Apr; 53(4):637-56. PubMed ID: 9098664 [TBL] [Abstract][Full Text] [Related]
17. Fosfomycin tromethamine for the Treatment of Cystitis in Abdominal Solid Organ Transplant Recipients With Renal Dysfunction. Kerstenetzky L; Jorgenson MR; Descourouez JL; Leverson G; Rose WE; Redfield RR; Smith JA Ann Pharmacother; 2017 Sep; 51(9):751-756. PubMed ID: 28511545 [TBL] [Abstract][Full Text] [Related]
18. The role of fosfomycin for multidrug-resistant gram-negative infections. Bassetti M; Graziano E; Berruti M; Giacobbe DR Curr Opin Infect Dis; 2019 Dec; 32(6):617-625. PubMed ID: 31567411 [TBL] [Abstract][Full Text] [Related]
19. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Enterobacteriaceae- related urinary tract infections. Tumturk A; Tonyali S; Tezer Tekce AY; Isikay L; Cime H J Infect Dev Ctries; 2019 Jan; 13(1):73-76. PubMed ID: 32032026 [TBL] [Abstract][Full Text] [Related]
20. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial. Rosso-Fernández C; Sojo-Dorado J; Barriga A; Lavín-Alconero L; Palacios Z; López-Hernández I; Merino V; Camean M; Pascual A; Rodríguez-Baño J; BMJ Open; 2015 Mar; 5(3):e007363. PubMed ID: 25829373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]